New Paper publication of financial results for Quarter and Half year ended 30 Sep,2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Concord Drugs Ltd has submitted to BSE the newspaper clippings of its unaudited standalone and consolidated financial results for the quarter and half year ended 30 September 2025, as required under Regulation 47 of SEBI's Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015. The results were published in Financial Express (English) and Prajasakti (Telugu) on 18 November 2025. For Q2 FY26 (standalone), the company reported revenue from operations of Rs. 1,027.85 lakhs, profit before tax of Rs. 27.13 lakhs, and profit after tax of Rs. 19.24 lakhs, translating to a basic and diluted EPS of Rs. 0.19. On a consolidated basis, Q2 FY26 revenue was Rs. 1,007.52 lakhs with a PAT of Rs. 19.39 lakhs. For H1 FY26 (standalone), revenue stood at Rs. 2,388.49 lakhs and PAT at Rs. 31.00 lakhs, while consolidated H1 revenue was Rs. 2,345.87 lakhs with PAT of Rs. 30.53 lakhs.
This is a routine regulatory filing confirming newspaper publication of already-disclosed results — no new information for investors. The headline financials show modest profitability with a small single-digit EPS, but the stock is a small-cap and the absolute numbers are limited; investors should focus on the detailed results filed separately with the exchange rather than this procedural disclosure.